
|Videos|October 7, 2020
Using the New Indication for Esketamine to Treat Patients with Major Depressive Disorder
Author(s)Gerard Sanacora, MD, PhD
Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.
Advertisement
Dr Sanacora is a Professor of Psychiatry at Yale University, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 7 - Interactive
2
Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression
3
Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice
4
Beyond Deprescribing: A Formula for Excellent Clinical Care
5










